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Peritoneal dialysis has long been used as an effective mode of 
therapy for both acute and chronic renal failure. Because of frequent 
hospitalization, individuals maintained in this way are often threatened 
with both local and systemic infection requiring treatment with broad- 
spectrum and species-specific antibiotics. Tobramycin and clindamycin 
are antimicrobials that fall into the above categories. However, because 
of the potential toxicities of these agents, rational therapeutics demand 
an accurate knowledge of drug disposition, since the additional modality 
of peritoneal dialysis places another variable on the clinical situation, 
thereby necessitating possible alteration in drug dosage. Because of 
the lack of data in this area, it is the purpose of this investigation 
to examine the pharmacokinetics and potential use of these agents in 
this patient population. 
A. Tobramycin 
Gram-negative bacilli constitute a frequent cause of serious infection 
in hospitalized patients. The aminoglycoside antibiotics have the broadest 
spectrum of antibacterial activity against these organisms. Nebramycin, 
an antibiotic complex of at least 7 factors, was first described by Stark, 
83 
et al, in 1967 and is a member of the aminoglycosides that also includes 
gentamicin, kanamycin, neomycin and streptomycin. Fermentation biosynthesis 
utilizing Streptomyces tenebrarius5,38:>66 produces the elemental parts89 
of which factor 6, tobramycin, has the greatest in vitro activity. Its 
47 
molecular formula is C-jgH^yN^Og*BH^O and it displays chemical behavior 
similar to that of other aminoglycosidic agents. 
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Tobramycin has excellent antibacterial activity against Pseudomonas 
aeruginosa and many of the Enterobacteriaceae.^5^5^5^ Most strains 
of Serratia, Providence, Streptococcus and Diplococcus pneumoniae are 
23 
resistant to attainable serum levels of tobramycin and although some 
5 23 
investigators report excellent anti-Staphylococcus aureus activity, ’ 
g 
others have found few isolates to be susceptible. 
Although the in vitro spectrum of activity appears to be similar 
90 
to that of gentamicin, the chief advantage of this agent would appear 
to be its greater activity against Pseudomonas. 9 Simon, et al, 
studied the in vitro activity of tobramycin against 100 isolates of this 
organism and found the MIC's to range from 0.63 to 1.25 mcg/ml for 81% 
of the isolates, whereas for gentamicin 85% were inhibited by concentrations 
of 1.25 to 2.50 mcg/ml. Since the therapeutic response to Pseudomonas 
16 17 
infection has been inadequate in some cases, ’ administration of 
tobramycin in identical dosage might be more efficacious. 
Synergy between penicillin and aminoglycosides against enterococci 
52 57 
is well known. ’ Although penicillin plus gentamicin has been shown 
to have excellent in vitro activity against all strains of enterococci 
58 97 
tested, 5 a significant number are resistant to the synergy of penicillin 
56 82 59 
plus streptomycin or kanamycin. ’ Moellering, et al, compared 
combinations of penicillin plus gentamicin and tobramycin against 27 
strains of enterococci isolated from blood culture. It was found that 
although tobramycin was synergistic against all strains of Streptococcus 
faecal is, it was ineffective against the four strains of S_. faecium tested. 
The combination of penicillin plus gentamicin was synergistic against 
all. 
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The toxicity of the aminoglycosidic group of antibiotics is well 
known and consists of both nephro- and ototoxicity. Ototoxicity is 
comparable to gentamicin and consists mainly of vestibular damage. 
Renal toxicity was studied by Wick and Wells'^ who found tobramycin 
less nephrotoxic than gentamicin. Overall, tobramycin is considered 
to have a level of toxicity similar to that of kanamycin, but less 
than either neomycin or gentamicin. 
Several investigators have studied the effect of dialysis on 
serum levels of the aminoglycosides, but the data is far from complete. 
Atkins, et al J documented the effect of peritoneal dialysis on the 
81 
half-life and clearance of kanamycin, while Smithvas, et al, made 
similar studies with gentamicin. The clearance and half-life of both 
50 
tobramycin and gentamicin were determined by Lockwood and Bower in 
anephrics before and after hemodialysis. However, except for the report 
98 
of one patient by Weinstein, et al , there is no information available 




Clindamycin [7(S) Chioro-7-deoxylineomycin] is an analogue of lincomycin 
from which it differs in the replacement of a hydroxyl group on C7 for a 
54 
chloride. Although the anti-bacterial spectrum of the two agents is 
similar, clindamycin has been shown to have greater in vitro and in vivo 
antibacterial activity against gram-positive aerobes, and gram-positive 
4 45 51 54 85 
and gram-negative anaerobic pathogens, including Bacteroides fragilis. ’ ’ ’ ’ 
Clindamycin phosphate is the water soluble ester and parenteral 
preparation of clindamycin- The phosphate is rapidly hydrolyzed to 
- 3 - 

biologically active free clindamycin and elimination is mainly via 
20 
hepatic and extra-renal mechanisms. Prolonged half-life, but normal 
92 
serum levels have been reported with impaired liver function. 
Modern anaerobic techniques permit the isolation of fastidious 
61 
anaerobes in many clinical settings. Aerobes, facultative and 
anaerobic species have been implicated as pathogens in lung abscess 
(often 2° to aspiration), empyema, pelvic abscess, peritonitis, bone 
and wound infection. 5 The prominence of anaerobes, in 
particular Bacteroides, is not surprising considering these organisms 
72 
comprise the majority of the flora found in the upper respiratory tract, 
32 31 
large bowel, and female genital tract. Bacteroides bacteremia is 
24 
no longer an uncommon occurrence. 
45 
In vitro studies by Kisi a k have shown clindamycin (median MIC 
0.19 mcg/ml) to be more active than lincomycin, chloramphenicol and 
tetracycline against 40 isolated strains of B. fragilis. Excellent 
clinical response to clindamycin therapy has been documented by several 
4 30 49 76 
observers. 555 it should be noted, however, that patients with 
abscess formation frequently relapse. Although certain cases require 
surgery, infection with multiple organisms is often the cause. In situations 
where both Enterobacteriacae and anaerobes are present, clindamycin alone 
37 
is probably not sufficient. 
Clindamycin is without apparent nephro-, hepato-, or ototoxicity, 
92 
However, transient leukopenia and eosinophilia along with rash, nausea 
and vomiting^ have been reported. Although preliminary studies^ 
indicated that clindamycin might have fewer gastrointestinal side effects 
than the parent compound lincomycin, reports of diarrhea and drug-induced 
_ 4 _ 

colitis began to accumulate as use of the drug became more widespread. 
Early reports listed the incidence of mild diarrhea varying from 4 to 
21 27 
33%. ’ In these cases, the onset was usually abrupt, and bloodless 
watery diarrhea without fever or leukocytosis was characteristic. 
12 
However, in 1973, Cohen, et al, reported 3 cases of pseudomembranous 
colitis. Patients manifesting this entity were febrile, had marked 
leukocytosis, and displayed proctosigmoidoscopic and roentgenographic 
evidence of severe mucosal ulceration, pseudomembrane and pseudopolyp 
93 
formation. The course of such patients was variable but in most cases 
was protracted, requiring hydration and often steroids both parenterally 
and per rectum. Whether opiates aggravate the syndrome is an area of 
40 
controversy. Most patients have not been seen to relapse after recovery. 
Briefly, pseudomembranous enterocolitis is characterized by 
inflammation and necrosis of the mucosa of the bowel. 5 The cause is 
not known but the syndrome has been associated with heavy metal poisoning, 
altered blood supply to the gut, post-operative states, staphylococcus 
g 
overgrowth, obstruction, and various antibiotics, including lincomycin, 
72 46 22 
ampicillin, L tetracycline, D chloramphenicol, L and neomycin. The syndrome 
may be clinically and roentgenographically indistinguishable from inflammatory 
13 
or vascular bowel disease. As noted above, the etiology of the disorder 
is not known. However, of the possibilities that have been suggested 
60 
one includes freed bacterial antigen interacting with host mucosa. 
The report^ of positive anti-nuclear factor in 2 of 4 patients with 
clindamycin-induced colitis, and the subsequent disappearance in one, 
again implies an immune mechanism. 
The original description of this drug-induced colitis have been 
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18 19 28 84 9Q 1D4 
subsequently confirmed in the literature. 9 9 9 9 9 Current 
evidence would, therefore, indicate that clindamycin is a therapeutic 
agent with potentially serious toxicity and should not be prescribed 
for minor infection where another, less toxic substitute will do. 
There are several studies on the use of clindamycin in patients with 
21 44 normal and impaired renal function. Joshi and Stein documented the 
serum half-life in uremics not on dialysis, while Cimino, et al,^ studied 
the pharmacokinetics in patients on hemodialysis. To date there have 
been no reports of half-life and clearance measurements of clindamycin 
68 in patients undergoing peritoneal dialysis, although Reinarz and McIntosh 
investigated the effect of azotemia, hemodialysis and peritoneal dialysis 
on the parent compound lineomycin. 
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II. MATERIALS AND METHODS 
A. Patients 
Outpatients of the Yale-New Haven and West Haven Veterans Administration 
hospitals with chronic renal failure comprised the patient population 
studied. All had been maintained on chronic peritoneal dialysis for at 
least 6 months, and had creatinine clearances less than 3 ml/min. None 
were septic, nor had any received antibiotics during the 2 week period 
prior to study. Informed consent was obtained from each patient after 
a detailed description of the procedures and potential complications. 
B. Dialysis 
All patients studied had permanent indwelling cannulae in place. 
Dialysis solutions (Dianeal 1.5 or 4.25% dextrose) were prewarmed to body 
temperature prior to infusion. Heparin was not added to the dialysate 
inflow. 
C. Administration of Antibiotics 
After a volunteer was selected for either the tobramycin or clindamycin 
study, the appropriate antibiotic was diluted in 100 ml of 5% dextrose 
in water, and administered intravenously over 20 minutes. The dosage for 
tobramycin and clindamycin were 1 mg/kg and 600 mg respectively. 
D. Protocol 
After taking a control serum specimen, the appropriate antibiotic 
was administered as described above. The beginning of the infusion was 
considered to be time zero. Another serum sample was drawn 5 and 30 minutes 
after the end of the infusion and dialysis was begun 30 minutes later. 
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Dialysis was performed according to the following schedule: 10 minutes 
to run into the peritoneal cacity, 20 minutes to equilibrate, and 30 
minutes to drain. The flow rate was 2 liters/hour. 
The dialysate from exchanges 1 through 7 and exchange 12 were 
collected in 2 liter dialysate bottles that had been previously autoclaved 
at 120°C, and serum samples were taken at 1.5, 2.5, 6.5, 7.5, and 12.5 
hours after the beginning of the study (time = 0). After the completion 
of the 12th exchange, which coincided with the 12th ancj f-jnal hour of 
the study, dialysis was then performed as per the dialysis unit. 
For clindamycin, serum samples were taken at 1.5, 3.0, 6.0, 9.0, 
and 12 hours. Dialysate was collected in the same manner as for tobramycin. 
E. Antibiotic Assays 
The assay for both tobramycin and clindamycin utilized the agar- 
diffusion principle. Wells of uniform size were cut in agar evenly seeded with 
an organism sensitive to the antibiotic to be assayed. When serum or 
dialysate containing antibiotic was placed in a well, a zone of inhibition 
surrounded by a background of dense bacterial growth resulted (Fig. 1). 
102 
By comparison to known standards, unknowns could be determined. 
Antibiotics: 
9 
(i) Tobramycin - modification of Micro-Agar plate for Tobramycin Assay, 
a. Materials: 
Plastic Petri Dishes - 150x15 mm (Lab-Tek No. 4028) 
Capillary tubes - Drummond "Microcaps": 10 microliter pipettes. 
(Drummond Scientific Co.) 
3 rnn cal ibrated 1 oop 
Caliper with vernier dial (Glogau & Co.) 
Modified Trypticase Soy Agar (TSA) - 26.66 gm TSA base/1000 ml; 
pH = 7.3 (Difco) 
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TSA slant 
Brain Heart Infusion Broth (BHIB) - (Difco) 
Pooled normal human serum 
Magnifier-Viewer - (National Instrument Laboratories, Inc., 
Rockville, Md.) 
12 gauge Jel co 
b. Organism 
Bacillus globigii, an unclassified spore-former. Maintained on TSA 
slant @ 4°C. with transfer to new media every 2 weeks. 
c. Method 
1) Calibrated loop was scraped along surface of TSA slant and 
organisms were inoculated into 30 ml of BHIB contained in 
a 50 ml Ehrlenmyer flask. Incubation for 6 hours @ 37°C 
yielded 10' - 10^ organisms/ml. 
2) 36 ml of melted TSA that had been cooled to 47°C in a 
water-bath, plus 3.0 ml B_. globigii were poured into a petri 
dish and swirled until adequate mixing had been achieved. 
Plates were allowed to cool and set at room temperature with 
the lids ajar for 20 minutes. 
3) Plates were stored 0 4°C until use for up to 5 days. 
4) Wells were punched in the agar with a 12-gauge Jelco (with 
the bevel ground off) attached to low suction. 
5) Antibiotic standard - Working laboratory standard: Equivalent 
to 1000 meg base per ml. Eli Lilly and Co. XU 5074 AMX. Assay 
standards were made in pooled normal human serum at the following 
concentrations (mcg/ml): 20.0, 10.0, 5.0, 2.50, 1.25, and 
were stored without loss of accuracy for up to 3 weeks. 
Peritoneal dialysate for use in making standards was collected 
during the week prior to study. All serum and dialysate 
unknowns were stored at -4°C along with the standards, and 
were assayed within 2 days of the study. 
6) Wells were filled until the meniscus was visible at the rim. 
Flooded or underfilled wells were discarded. A full set of 
standards accompanied unknowns on every plate and plates 
were done in duplicate. 
7) Plates were then incubated for 6 hours @ 37°C. 
8) Zones of inhibition were measured with the aid of both a viewer 
equipped with a magnifying stage, and vernier calipers. 
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91 
(ii) Clindamycin - Modification of Serum Clindamycin Assay Procedure. 
Assay similar to that outlined for tobramycin, and differs only as noted 
be! ow. 
a. Materials: 
Capillary tubes - Yankee No. 1021 Microhematocrit tubes/Plain. 
75x O.D. 1.50 mm (I.D. 1.10 mm). (Clay Adams). 
Penassay Broth (PAB) - B243 (Difco) 
Penassay Seed Agar (PAA) - B263 (Difco) 
Nutrient Agar (NA) - B1 (Difco): NA slant 
Stainless steel punch - O.D. 0.4 cm 
b. Organism 
Sarcina lutea - ATCC 9341. maintained on NA slant 0 4°C with 
transfer to new media every 2 weeks. 
c. Method 
1) Inoculum into PAB. Incubated for 16 hours @ 37°C. 
2) 36 ml melted PAA plus 3.0 ml S_. 1 utea (16 hour culture). 
4) For antibiotic assay in the range 5 mcg/ml to 20.0 mcg/ml, 
12-gauge Jelco punch was used to make wells. A larger punch 
(0.4 cm O.D.) was used for determinations in the range 0.5 
mcg/ml to 5.0 mcg/ml . 
5) Antibiotic standards - Working laboratory standard: 1000 mcg/ml 
of cl indamycin-2-P04 8760-AJS-115-11 (841.5 meg base equivalents/mg). 
Assay standards were made in pooled normal human serum at the 
following concentrations (mcg/ml): 22.5, 7.50, 3.76, 1.88, and 
.98. Standards were treated with phosphate buffer 0 pH = 8.0 
in order to allow measurement of "free clindamycin."21 
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III. DATA ANALYSIS 
A. Serum and Peritoneal Dialysate Antibiotic Levels 
The diameter of the zones of inhibition of growth were measured to 
the nearest 0.1mm with vernier calipers and the magnifying viewer. When 
solving graphically, triple cycle semi 1ogarithmic paper is used. The 
concentration of the antibiotic standard (mcg/ml) is plotted on the y-axis 
(ordinate), and the corresponding zone sizes on the x-axis (abscissa). 
The best straight line approximating these points is drawn, and using 
the zones of inhibition they produce, the unknowns can then be extrapolated 
from the graph. The range of the assay is 0.6 to 20.0 mcg/ml. 
In an attempt to increase both the speed and accuracy of the above 
analysis, the Monroe Statistical Calculator (model 1930) was utilized 
to perform linear regression analysis on the standard data and thus 
provide an equation of the form y = mx + b describing the best straight 
line for that data. In this equation 
y = log (concentration of antibiotic mcg/ml) 
m = slope 
x = diameter of zone (cm.) 
b = y intercept when x = 0 
The calculator provides both m and b. Therefore, if the diameter 
of the zone of inhibition for an unknown is substituted into the equation then 
y = mw + b = z 
x = w 
Z represents a number that is a logarithm. In order to transform this 
value back to a concentration in mcg/ml, the inverse function of log must 
be allowed to operate. If v is the unknown concentration, then 
y = z = log v 
ey = ez = elo9 v = mcg/ml 
11 

In this way, all the assay results for both tobramycin and 
clindamycin were evaluated. As the determinations were done in duplicate, 
serum and dialysate values were expressed as the mean ± the standard 
deviation (S.D.) 
B. Clearance 
In renal physiology, clearance is considered to be the smallest 
volume of plasma from which the kidneys can obtain the amount of the 
75 
substance excreted per minute. In this study, a similar definition 
can be used and the following equation results: 
C = (D x V)/S 
where C = clearance (ml/min) 
D = dialysate concentration (antibiotic: mcg/ml; 
creatinine or urea: mg%) 
V = volume of dialysate (ml/hr) 
S = serum concentration (mcg/ml or mg% as above) 
As outlined in the protocol, the duration of each exchange was 1 
hour. V was determined by measurement of the total dialysate drainage 
for that exchange period. S was determined from a serum sample taken 
at the midpoint of that exchange period and was considered to be an 
approximation of the mean serum level of urea, creatinine or antibiotic 
during that exchange. The serum decay curve of the antibiotic was 
utilized to estimate the mean serum antibiotic level for exchanges where 
no serum sample was taken. 
The peritoneal clearance of urea, creatinine and administered antibiotic 
was calculated. 
C. Amount of Antibiotic Removed 
This quantity was calculated by the following equation: 
- 12 

V' x D = A 
where V' = volume of dialysate (ml) 
D = dialysate antibiotic concentration (mcg/ml) 
A = amount of antibiotic removed/exchange 
The total antibiotic removed over the 12 hours of dialysis was estimated. 
It should be noted that exchanges 8 through 11 were not collected. An 
approximation of the antibiotic concentration was made by taking the 
mean value of exchanges 7 and 12. 
D. Half-Life: T1/2 
The pharmacokinetic behavior of administered drugs can be thought 
of in terms of several types of compartmental models: 







(ii) 2-Compartment: Assumes instantaneous distribution within 
a central compartment (e.g. blood, ECF etc.), and a 
slower distribution into a peripheral compartment 
(e.g. intracellular space). 
I.V. CENTRAL COMPARTMENT 
kJ2^ 
PERIPHERAL COMPARTMENT 
DOSE NO 1 
k21 
NO. 2 
ik‘* = kel 





(iii) 3-Compartment: A central compartment, as above with distribution 
into 2 peripheral compartments at differing rates. 
Although the above models are useful in explaining the kinetics of 
drug disposition, it is important to note that in some cases, there 
may be little physiologic basis for their actual existence. 
Drug distribution in the most complex of systems can theoretically 
be described by a multi-compartmental model. However, although Riegelman, 
69 
et al , suggested that a bi- or tri-exponential function could accurately 
describe distribution of an administered drug, it was Sharney and co- 
78 
workers who were able to mathematically reduce a large number of 
interchanging pools to a 2 or 3 compartment model. 
We can, therefore, attempt to describe the kinetics of the present 
69 
study by the 2-compartment open system as outlined by Riegelman. Here, 
the serum concentration Cp at any time t is given by the equation: 
Cp = A e"at + B e"bt 
The coefficients A and B, along with the hybrid rate constants a and b 
86 
can be determined by graphical analysis, or by computer determination 
(BMDP3R - Nonlinear regression analysis - IBM 360. See Appendix) 
When adequate numbers of serum samples are taken after the intravenous 
administration of a drug, an equation of at least 2 exponential terms 
in the form seen above is obtained. Although it is usual practice to 
call b the elimination rate constant, it can be seen from Fig. 3 that 
k -j is the appropriate constant, a and b can be shown to be hybrid rate 
69 
constants , their magnitude being dictated by the rate constants 
participant in the overall kinetics of the system. The actual relation 
between k^ and b is given by 




Wagner, et al, showed that when the volume of the peripheral compartment 
was much greater than the central , and the rate constant k^ much 
greater than , the T-^ estimate 0.693/b will overestimate the half- 
life, b is, therefore, a function of both Vcentral/Vperiphera) and K,2/keK 
Thus, when b is not a good estimate of k^ , T-^ is best calculated by 
the equation 
T-j - 0.693/ke-| where 
kel = ab (A + B)/(Ab + Ba)94 
In the present study, the coefficients and rate constants of the 
. b "t 
relation Cp = Ae" z + Be-0 were determined by either graphical or 
computer analysis to the same degree of significance. The calculated 
half-life for each drug is reported as: 
(i) T-i /ob - The parameter b estimates the slope of the terminal 
/ log-linear section of the serum decay curve and is 
related to the T,/? by the following expression: 
T-,= 0.693/b. ' Determination of half-life by 
'this method assumes monoexponential decay. 
(ll) T1/2kel- Utilization of all the coefficients and rate constants 
of the bi-exponential formulation result in determination 





related to T-^ by the expression: T-j^^el = 0,693/ 
E. Volume of Distribution 
The volume of distribution (L), is simply a proportionality constant 
used in pharmacokinetics, and has no real physiologic significance. One 
definition is, that volume of fluid into which the drug apparently distributes 
86 
with a concentration identical to that in blood. Vd can be calculated 
in several ways, the most common being graphically. Analysis by this 
method assumes monoexponential decay during elimination and simply involves 
the extrapolation of the straight linear terminal portion of the decay curve 
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back to time = 0. This results in determination of the serum concentration 
at this time, and is designated Cp°. can then be calculated by the 
rel ation: 
= D/Cp° where D = administered dose (mg). 
If, however, the decay curve cannot be accurately estimated by 
a single exponential function, then it must be assumed that at least 
a 2-compartment model is necessary to describe the system. The of 
the two compartment open system is more complicated and can be determined 
86 
by the following equation: 
(Vd)b = Da/(Ba + Ab) where D = administered dose 
a,b = hybrid rate constants 
A,B = exponential coefficients 
Vj is useful in that it is inversely proportional to the peak serum 
concentration Cp° and can be used to estimate this value at varying dosages. 
F. Area Under The Curve: A 
The administered dose can be represented by the area under the 
intravenous concentration-time curve. This can be calculated by either 
taking the integral of the function describing the serum decay (with 
appropriate time limits), or by numerical integration using the trapazoidal 
, 86 
rul e. 
In this investigation, the mean values for serum levels were plotted 
and used to construct a mean serum decay curve. The area below the curve 
from 0 to 12 hours was determined by the trapazoidal rule. 
G, Error Analysis 
All serum and dialysate assays were done in duplicate on each plate. 
Each unknown was done on duplicate plates in order to insure reproducibility 
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of results. Plate-to-plate coefficient of variation was - 10%. All 
values are, therefore, reported as the mean of those obtained on two 
independent determinations. The error is reported as + the standard 
deviation of the mean (SD). 
All other values (e.g. C, V^, Tetc.) are reported as the mean 
± the standard error (SE). 
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IV. RESULTS 
There were no complications during the present investigation except 
for patient #4 who accumulated approximately 5 liters in his peritoneal 
cavity during the 12^ exchange of the tobramycin study. The fluid 
subsequently drained without incident. 
A. Tobramycin 
1) Serum and Peritoneal Dialysate Antibiotic Levels: In the 5 
patients studied, the mean peak serum concentration (Table 1, Fig. 4) was 
4.66 mcg/ml (range: 3.29 - 7.36) recorded at 5 minutes post infusion. 
After 12 hours of dialysis, at a flow rate of 2 liters/hour, this level 
fell to 1.64 mcg/ml (range: 1.26 - 2.10). The mean peritoneal dialysate 
concentration (Table 2) was 0.91 mcg/ml (range: 0.79 - 1.07) over the 12 
hours of dialysis. 
2) Clearance: The individual values for the clearance of tobramycin 
are listed in Table 2. The mean clearance was 14.98 ml/min (range: 12.31 - 
20.01). Similar calculations for urea and creatinine yield values of 
26.82 ml/min (range: 25.08 - 30.55) and 23.99 ml/min (range: 23.77 - 24.50) 
respectively (table 10). The ratios of the respective clearances along 
with pre- and post-dialysis serum levels of urea and creatinine are given. 
3) Total Amount of Antibiotic Removed by Dialysis (Table 2): The 
mean quantity of antibiotic removed after 12 hours of dialysis was 21.00 
mg (range: 17.30 - 25.43). This resulted in 33.9% removal of the initial 
1 mg/kg dose. 
4) Half-life: T(Table 3): Graphical and computer analysis yielded 
the coefficients A, B, a and b (Table 6). Utilizing these values two 
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estimates of Twere obtained: 
(i) Ti/2^5 which utilized the slope of the terminal log-linear 
segment of the serum decay curve, was 16.08 hours (range: 8.88 - 19.25). 
(ii) Ti/2^el ’ whl'ch was calculated assuming applicability of the 
2-compartment model, was found to be 10.74 hours (range: 8.90 - 13.05). 
The T-j/2 calculated from the tail portion of the average serum decay 
curve (Fig. 4) was 14.44 hours. 
5) Volume of Distribution: V^, (V^)^ (Table 4): The mean for 
the 5 patients studied was 21.40 liters (range: 16.07 - 31.28) which 
represented 34.34% of total body weight (BW) (range: 27.93 - 44.10). 
(Vd)b» which is based on the 2-compartment model, was calculated to be 
22.93 liters (range: 15.71 - 32.77) and represented 36.35% of BW (range: 
28.83 - 46.15). 
6) Area under the Serum Decay Curve: A-p For the 12 hours of study, 
Ay was found to be 28.54 (mcg/ml)(hour). 
B. Clindamycin 
1) Serum and Peritoneal Dialysate Antibiotic Levels: In the 3 patients 
studied, the mean peak serum concentration (Table 8, Fig. 5) was 15.41 
mcg/ml (range: 13.78 - 16.82) recorded at 5 minutes post infusion. After 
12 hours of dialysis, at a flow rate of 2 liters/hour, this level fell 
to 1.39 mcg/ml (range: 0.66 - 2.58). 
Clindamycin levels were determined on dialysate from exchanges 1, 3, 
and 6. Only exchange 1 had detectable anti-bacterial activity (Table 5). 
The mean dialysate concentration for this exchange was 1.81 mcg/ml (range: 
1.42 - 2.53). 
2) Clearance: The mean clearance for the three patients studied was 
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4 ml/min during the first exchange. Urea and creatinine clearance were 
not determined during this study. Pre- and post-dialysis serum urea and 
creatinine levels are listed in Table 8. 
3) Total Amount of Antibiotic Removed by Dialysis: The mean quantity 
of antibiotic removed during the first exchange was 3 mg. 
4) Half-Life: T-^ (Table 5): Graphical and computer analysis yielded 
two estimates of T 
(i) /2b’ utilized the slope of the terminal log-linear segment 
of the serum decay curve, was 4.55 hours (range: 2.22 - 6.42), and 
(ii) Ti/^ei , calculated assuming applicability of the 2 compartment 
model, was 2.81 hours. The T-^ determined from the tail portion of 
the average serum decay curve (Fig. 5), was 6.79 hours. 
5) Volume of Distribution: Not determined in the present investigation. 
6) Area under the Serum Decay Curve: A^: A^ was found to be 49.88 
(mcg/ml)(hour) for the 12 hours of study. 
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V. DISCUSSION 
A. Effect of Peritoneal Dialysis on Urea and Creatinine Disposition 
The clearance of urea and creatinine in patients undergoing peritoneal 
dialysis was documented in four of the five patients who underwent study 
with tobramycin (Table 10). The mean values for urea and creatinine 
clearance were 26.82 and 23.99 ml/min respectively. These values are 
greater than the clearances in a similar patient population reported by 
Nolph, et al, D (Table 11). This finding may be secondary to the inter¬ 
mittent use of hypertonic dialysate (Dianeal 4.25% dextrose) during the 
present study. It has been demonstrated^3 that ultrafil tration across 
the peritoneal membrane is enhanced with the use of hypertonic dialysis 
solutions. Henderson and Nolphi /D concluded that the alteration in 
peritoneal transport was secondary to a significant increase in membrane 
permeability, and additionally showed that increased transperitoneal 
transport persisted during subsequent exchanges that utilized isotonic 
dialysate. 
63b 
The study reported by Nolph, et al, u utilized isotonic dialysate, 
and it is, therefore, understandable that the clearances documented in 
the present study are greater than previously reported values. 
B. Tobramycin 
It was stated at the outset that although there was little data on 
the use of tobramycin in patients undergoing peritoneal dialysis, the 
pharmacokinetics of the drug in renal disease were known. Naber, et al, 
found peak serum values, after an initial dose of 1 mg/kg administered 
intravenously, in normals and patients with impaired renal function (highest 
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creatinine = 3.8 mg%) to be approximately 6.8 and 9.2 mcg/ml respectively. 
In contrast, the present study found peak levels of 4.66 mcg/ml (Fig.4 ) 
in 4 patients who were essentially anephric (creatinine clearance - 3 
ml/min). This difference would appear to be significant. One possibility 
that serum levels are not as high as would be expected from previous 
studies may be explained by noting that although tobramycin appears to 
distribute rapidly into a volume comparable to the extracellular space 
80 
in patients with normal renal function, there is probably distribution 
into a larger space in patients with significant renal impairment. This 
greater volume of distribution is most likely secondary to penetration 
of the drug into the intracellular compartment, 
80 
Simon, et al , compared the pharmacokinetics of tobramycin and 
gentamicin in normals. The for tobramycin was found to be 16.9 liters 
by constant infusion studies. This value was not statistically different 
from that obtained for gentamicin, and it can therefore be concluded 
that both antibiotics distribute into a compartment slightly larger than 
the extracel 1 ular space. Although there is no data reporting the of 
tobramycin in anephrics, such information is available for gentamicin. 
36 
Gyselynck determined the of gentamicin in several patients with inulin 
clearances of less than 7 ml/min, and found their mean to be 41.0% BW 
(range: 32.9 - 51.9) by single intravenous injection studies similar to 
those performed in the present investigation. Clearly, the for patients 
with severe renal impairment is much greater than that observed for normals, 
and may approach a volume eaual to total body water. 
Based on the above data for gentamicin, it could be postulated that 
similar values would be obtained for tobramycin in patients with severe 
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renal impairment. The results of the present study substantiate this 
hypothesis in that the determined graphically in 5 patients studied 
was found to 21.40 liters (34.34% BW). Therefore, a significantly larger 
volume of distribution exists in functionally anephric patients, when 
compared to the in normals as described above. This being the case, 
the lower than expected peak serum levels are understandable and can be 
described by the relationship: 
Cp° = D/Vd where D = administered dose (mg) 
As increases, the peak serum level falls. 
62 
It must be noted, however, that Naber, et al, determined the 
in patients with renal impairment (highest creatinine = 3.8 mg%) and 
found no statistical difference from that obtained in normals. It is 
concluded that large volumes of distribution are seen only with severe 
renal failure. This idea is corroborated by the data presented by 
36 
Gyselynck for gentamicin in that very large volumes of distribution were 
seen only with extensive renal dysfunction. 
The above discussion of increased distribution space found in the 
present study can be criticized because simultaneous studies with inulin 
were not performed. However, because of the similarity in behavior of 
tobramycin and gentamicin concerning the parameter V^, the explanation 
given follows logically from the known data. Further investigation might 
attempt to more fully delineate the in patients with severe loss of 
renal function. 
Another possibility for the finding of lower peak serum levels is 
difference in assay technique. Control samples and assays done in duplicate 
were used in an effort to minimize such variation. 
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Several antibiotics have been studied in patients undergoing peritoneal 
29 35 73 79 
dialysis. 5 ’ 9 Of the aminoglycosides, kanamycin and gentamicin 
have been the most extensively characterized. Atkins, et al J determined 
the effect of dialysis on kanamycin disposition in anephrics. Over a 
period of dialysis lasting 22 hours, at a flow rate of 3.5 liters/hour 
(range: 2.1 - 4.5), 32l of the administered dose was removed at a mean 
clearance of 8.3 ml/min. Half-life of the drug was reduced from 84 hours 
to 12. This data indicates the need for alteration in drug dosage 
schedules in order to maintain adequate serum antibiotic levels. The 
above study both corroborated and expanded on the earlier reports concerning 
35 
kanamycin by Greenberg, et al . 
The effect of peritoneal dialysis on the distribution of gentamicin 
27 
in patients with and without peritonitis was studied by Smithvas, et al. 
Of those patients with documented peritonitis, the passage of gentamicin 
from serum to dialysate was found to be quite variable. Therapeutic 
levels of antibiotic were achieved in the peritoneal dialysate in 5 of 
8 patients after 36 - 48 hours without evidence of serum accumulation. 
These patients were receiving 80 mg intramuscularly every 12 hours. Dialysate 
levels in these patients ranged from .70 to 3.90 mcg/ml, with a mean at 
48 hours of 2.0 mcg/ml. On the other hand, 3 of the patients studied 
developed excessive serum levels (> 10.0 mcg/ml). Only 2 patients without 
81 
peritonitis were studied by Smithvas and co-workers, and while neither 
developed therapeutic dialysate concentrations after 48 hours of a dosage 
schedule identical to that for patients with peritonitis, one did develop 
toxic serum levels (15.5 mcg/ml). 
The data shows removal of gentamicin in this patient population to 
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be a function of the degree of peritoneal inflammation. Clearances 
varied from 7.9 ml/min to 12.4 ml/min with corresponding half-lives 
of 15.0 to 5.3 hours in 3 patients with clinically documented peritonitis. 
The amount of drug removed ranged from 40 to 70 mg/day. In one of the 
2 patients studied without peritonitis, the clearance was calculated 
to be 4.9 ml/min, the removal rate 10.5 mg/day, and the half-life 28.5 
hours. Summarizing, the removal rate in patients without peritoneal 
inflammation was 15 to 25% of that seen with peritonitis and the T-^ 
27 
was prolonged 2 to 5 times. 
It should be noted that the above study has several limitations 
in that much of the data was collected on less than 3 patients and 
dialysis was not uniform over the period of study. Approximately 2 liters 
were exchanged each hour with equilibration time varying from 0 to 20 
minutes. Lastly, the calculation of serum half-life assumed monoexponential 
decay. 
Although there are no well controlled studies of the peritoneal 
98 
clearance of tobramycin anephrics, there is a report by Weinstein, et al, 
of one patient who first received gentamicin, and then tobramycin for 
extensive Pseudomonas pneumonia while being maintained on peritoneal 
dialysis for acute tubular necrosis. Dialysate antibiotic levels were 
reported between 0.5 and 1.5 mcg/ml. It should be noted, however, that 
this particular patient retained some degree of renal function during 
the study, and achieved urinary concentrations of the drug in the range 
16 to 49 mcg/ml. It was estimated that 48 hours after a 90 mg initial 
intramuscular dose, approximately 35 mg underwent renal clearance while 55 
mg was removed by peritoneal dialysis. However, this situation was poorly 
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controlled by definition in that the use of tobramycin was limited to 
one patient who was critically ill, had received previous antibiotics, 
and retained some degree of renal function. In addition, dialysis 
exchanges were performed every 1 to 2 hours with 2 liters of dialysate 
43 
with added heparin. Jackson reported that heparin, in sufficient 
quantity, led to inhibition of aminoglycoside antibacterial activity. 
Clearly such action would interfere with the bacteriologic assay as 
described earlier. These observations make it difficult to make a 
generalized statement about the efficacy of peritoneal dialysis in 
removing tobramycin. 
The Tof tobramycin in anephric patients not on dialysis as 
50 
determined by Lockwood and Bower was 53.4 hours. In patients with 
creatinine clearances of 9.5, 5.0 and less than 2 ml/min, the T-^ for 
each was 19.5, 36.4 and 56.0 hours respectively. They additionally 
reported identical half-lives for gentamicin and tobramycin in anephric 
patients. 
The cumulative data of previous studies is summarized in Table 7. 
Clearly, differences exist between the three antibiotics listed, but some 
similarities are evident. To begin with, the results of the present 
study show the effect of peritoneal dialysis on tobramycin half-life to 
be similar to that seen with kanamycin in the absence of peritonitis. 
Comparison to gentamicin reveals half-life and clearance similar to that 
seen in patients with peritoneal inflanimation. 
Looking more closely at the result of the present study, a significant 
reduction in serum T^^ 1S seen. When determined using the terminal log- 
linear portion of the serum decay curve, the mean T-^b for 5 patients was 
- 26 

16.08 hours (Table 3). Comparison to the value of 53.4 hours in anephrics 
indicates a significant reduction of T^ resulting from dialysis. As 
discussed in the section on data analysis, calculations utilizing b only 
may overestimate the true T-j^ ^ assuming that the serum decay curve 
is monoexponential. When plotted semilogarithmically the collected 
data shows this type of serum decay in antibacterial activity only after 
several hours. To ignore this early portion of the decay curve would 
result in unfair bias of the data because in some cases, this period of 
time represents a significant portion of the overall period of study. 
When the 2-compartment open system was used to analyze the data, the 
mean T-^ °f 4 patients, calculated from the coefficients and hybrid 
rate constants of the equation y = Ae"at + Be-^ (Table 6), was 10.74 
hours. However, regardless of the method used, the results indicate 
significant removal of the drug and reduction of serum half-life. 
As stated earlier, the T-^ obtained for tobramycin in the present 
study is comparable to that seen for gentamicin in patients with peritoneal 
inflammation (gentamicin T-^ range: 5.3 - 15.0 hours). This is sub¬ 
stantiated by the similarity of clearance values for both drugs (tobramycin 
14.98 ml/min, gentamicin: 7.9 - 12.4 ml/min). Comparison to the single 
patient receiving gentamicin who did not have peritoneal inflammation, 
shows the T-j ^ of 28.5 hours to be significantly prolonged relative to 
that obtained for the 5 patients in the present study. The explanation 
for these findings is difficult, but the lack of uniformity in dialysis 
and the limited number of patients in the gentamicin study may be partially 
responsible for the differences seen. An additional important factor is 
o 7 
variation in the patient population studied. It has been reported that 
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the ability of the peritoneum to function effectively as a semipermeable 
membrane may become compromised with recurrent bouts of peritonitis. 
The previous history of the single patient without peritoneal inflammation 
81 
studied by Smithvas and co-workers, is unknown. In addition, the 
patients who were studied while having documented peritonitis may have 
indeed undergone several similar episodes, each possibly resulting in 
progressively more scarring and fibrosis of the peritoneal membrane. 
Therefore, if it is assumed that for "small" solutes (molecular weight 
(MW)<. 40,000), such as urea (MW=60), creatinine (MW=113) and the amino¬ 
glycosides, the major path of transport from the capillaries to the 
44a 
peritoneal fluid is via intercellular channels, then alteration in 
the size, shape or change of these "functional pores" may reduce permeability 
Finally, Bulger, et al reported the variability displayed in peritoneal 
diffusion of the same antibiotic in different patients. It is concluded 
that the difference seen between gentamicin and tobramycin as described 
above, may be secondary to variation in patient population, lack of 
sufficient sample size and variation in dialysis technique. 
The fact that the present study shows tobramycin to be dialyzable is 
33 
supported by the recent investigation by Gordon and co-workers who studied 
the serum protein binding of aminoglycosidic agents. The degree to which 
a drug is protein bound has been shown to influence not only the therapeutic 
action, but also the pharmacokinetics of that agent. The aminoglycosides 
oo 
are excreted by glomerular filtration, the amount filtered being 
F)7 - 
proportional to the concentration of unbound drug. This is analogous to 
clearance across the peritoneal membrane. Drugs of high protein binding, 
such asdoxycycline (protein binding 93%) are poorly removed from the 
serum in patients undergoing peritoneal dialysis,63 while those of low or 
63a 
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minimal binding such askanamycin*^ are dialyzed quite wel1 . ^ 
Using ultrafiltration techniques, Gordon, et al, were able to show 
the protein binding of kanamycin, gentamicin and tobramycin to be 
essentially zero, while that for streptomycin was found to be 35%. 
The values obtained by these studies for kanamycin and streptomycin agree 
with previous investigations^’^, while those for gentamicin are at 
variance with the previously reported estimates of 30% gentamicin 
protein binding.^ 
That gentamicin is now reported to be minimally protein bound, if 
at all, is not surprising in view of the several investigations that 
have compared the clearance of this agent to that of inulin, a substance 
excreted only by glomerular filtration.^6 The clearances were shown to 
be almost identical. However, if only 70% of gentamicin in the serum 
could be considered to be ultrafi1trable, net tubular secretion of the 
drug would have to be postulated in order to explain the observed data. 
Similarly, studies comparing the clearance of tobramycin and inulin*^ 
obtained comparable results, in addition to showing the lack of probenicid 
effect. It would appear, therefore, that tubular secretion of these 
drugs was proposed in an effort to rationalize data that indicated pure 
glomerular filtration as the mechanism of renal excretion. However, if 
the protein binding of gentamicin and tobramycin is negligible, as 
suggested by Gordon, et al ,^3 then no tubular mechanisms need be proposed 
to explain the observed data, since the drugs are essentially 100% 
ultrafi1trable. 
Finally, comparison of the clearance of tobramycin to that of urea 
and creatinine should be noted (Table 10). If intercellular channels 
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are considered to be the major path of transport from capillaries to 
peritoneal fluid,and it is assumed that substances of greater 
molecular weight will have increased difficulty traversing these 
channels,it is expected that CtQbra would be less than either Curea 
or Ccr. The molecular weight of tobramycin is 519 (as the trihydrate) 
and, as expected, ^ is less than that observed for urea or creatinine, 
substances of considerably smaller molecular weight. It is concluded 
from the present study that a substance of minimal (or zero) protein 
binding and low molecular weight will be dialyzable. 
Therefore, the present data, that the clearance and half-life 
of tobramycin are similar to that of kanamycin, is not surprising. The 
fact that gentamicin does not display similar behavior may be explained 
by considerations dealt with earlier. 
At the outset, it was stated that tobramycin was a broad-spectrum 
antibiotic with excellent activity against Pseudomonas aeruginosa. Based 
on the result of the present investigation, recommendations as to the 
use of this agent in both local and systemic infection can now be made. 
(i) Systemic Infection 
An optimal dosage schedule requires maintainance of antibiotic 
levels that are both therapeutic and non-toxic. In formulating such a 
regimen, it is clear that the volume of distribution must be considered. 
As noted earlier, the undergoes considerable variation with alteration 
in renal function and is increased with severe renal insufficiency. The 
net result is lower peak serum levels. Of additional importance in 
dosage considerations is the range of bacterial sensitivity. The anti¬ 
bacterial spectrum of tobramycin and bacterial sensitivities were outlined 
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in the Introduction and will not be repeated here except to mention the 
1 8 
report of Bodey, et al , documenting the susceptibility of 457 clinical 
isolates of gram-negative bacilli at an MIC of 1.56 mcg/ml. 
If it is assumed that a peak serum antibiotic level (P^) of 6 
mcg/ml results in adequate therapeutic levels, distributed into a volume 
of approximately 35% BW (compromise between 1- and 2-compartment analysis), 
then drug dosage can be estimated for this patient population by the 
following calculations: 
= 6 mcg/ml = 35% BW = 25 liters 
BW = 70 kg 
then 
Dosage (mg/kg) = (P^MV^) = (6 x lCT^g/ml) 0.025 x 10+^ml) 
BW ~ 70~kg 
Dosage = 2 mg/kg 
When administered every third half-life, this dose of antibiotic will 
result in the calculated peak serum level, but the usual peak-trough effect 
will be present. When dealing with a sensitive organism, such variation 
15 
in serum levels is acceptible. It has been shown by Cutler, et al, that 
in patients with renal failure a more stable drug level is attainable, 
with less variation between doses, by administering one-half the loading 
dose every half-life. 
Looking at Table 3, it is seen that there are two estimates of half- 
life based on the data collected in the present study. Inasmuch as neither 
value is to be considered absolute, and in order to facilitate drug 
administration, a half-life of 12 hours will be used in calculating the 
dose interval. Therefore, the suggested dosage schedule is given as follows 
31 

Loading Dose - 2 mg/kg 
then either 
(a) loading dose given every third half-life (36 hours) 
or 
(b) one-half the loading dose given every half-life (12 hours) 
(ii) Peritonitis 
Peritonitis has always been a serious complicating event in the 
natural history of patients maintained on peritoneal dialysis, and is 
usually defined as a syndrome comprised of abdominal pain, fever and 
41 
bacteriologic confirmation of infection. 
The present study found levels of tobramycin in the dialysate to 
range from 0.44 to 1.60 mcg/ml , (See Appendix) with a mean of 0.91 mcg/ml. 
Based on in vitro studies presented earlier, these levels would not be 
bactericidal for many gram-negative organisms. Similar data was presented 
for gentamicin. 
In addition to patient variability, the fact that the dialysis 
solution if removed before equilibration with the serum is achieved, 
usually precludes the possibility of therapeutic dialysate concentration 
being attained. It should be noted, however, that none of the patients 
in the present study had peritoneal inflammation. It can, therefore, be 
expected that with peritonitis, some patients may achieve therapeutic 
81 
levels as evidenced by the data given for gentamicin. However, because 
of the uncertainty in maintaining adequate peritoneal fluid levels of 
antibiotic, this problem has long been dealt with by the use of intra- 
14 74 
peritoneal drug administration. 5 It is recommended that in order to 
insure adequate dialysate bactericidal activity, tobramycin be added to 




Studies on the intraperitoneal administration of gentamicin in 
patients with peritonitis have shown equilibration between dialysate 
and serum after 12 hours. However, because of the 12 hour delay before 
41 
sufficient serum levels are achieved, Hyams, et al, administered an 
initial 80 mg intramuscular dose followed by 5 mg/liter intraperitoneally. 
This regimen resulted in equilibration between serum and peritoneal fluid 
in the range 1.5 to 5.0 mcg/ml. When 10 mg/ml were given intraperitoneally, 
equilibration levels varied from 1.4 to 13.0 mcg/ml. Unlike some 
antibiotics, such as tetracycline, serum accumulation does not appear to 
occur with gentamicin even after repeated intraperitoneal administration 
which suggests that significant extra-renal clearance exists for this 
agent. Assuming the applicability of the above data to tobramycin 
disposition, and the present data, it may be concluded that bactericidal 
serum and dialysate activity can most rapidly be achieved by administering 
a parenteral loading dose, followed by intraperitoneal administration 
every 12 hours. Therefore, the suggested dosage schedule for tobramycin 
in patients with documented peritonitis is given as follows: 
Loading Dose - 2 mg/kg 
then 
5 mg/liter every 12 hours 
Finally, it should be emphasized that the variables and assumptions 
in the formulation of these regimens are multiple. Although a plan of 
therapy is suggested, it is advised that serum and dialysate levels of 
tobramycin be determined by the assay procedure outlined earlier. Both 
the speed and the accuracy of this determination make it possible to 
monitor body fluid drug levels and thereby allow for patient-to-patient 
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variability. This approach yields optimal patient care. 
C. Clindamycin 
Although there have been no studies reporting the effect of peritoneal 
dialysis on clindamycin disposition, data is available for both normal 
and impaired renal function. The pharmacokinetics of the parent compound, 
lincomycin, have been documented in normals, uremics and in patients 
undergoing dialysis. 
In the present study, the average peak serum level of antibiotic 
for 3 patients studied, was found to be 15.41 mcg/ml in samples obtained 
5 minutes after the end of the 20 minute intravenous infusion (Table 8, Fig. 5). 
This value is considerably greater than the 8.42 mcg/ml reported by 
21 
DeHaan. In addition, serum levels obtained in the present study were 
uniformly greater than those seen in patients with normal renal function, 
and were equal to the levels expected after a 1200 mg intravenous dose. 
44 
This finding is similar to that reported by Joshi and Stein who found 
serum levels in anephrics after a 300 mg dose to be elevated approximately 
2.5 times those seen in normals. Comparing the results of the present 
study, in which 600 mg of clindamycin was administered intravenously, 
to the above investigation, the mean peak serum concentrations were 
observed to be 1.25 times greater with the larger dose. Serum levels of 
lincomycin anephrics is similar, with peak concentrations being greater 
68 
than those obtained in normals by a factor of 3.25. 
Assay determinations on samples of peritoneal dialysate showed no 
antibacterial activity after the initial exchange. The mean dialysate 
concentration during the first hour of dialysis was 1.81 mcg/ml. The 
present study shows that except for minimal early drug clearance, clindamycin 
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is not dialyzable. It is, therefore, expected that this agent is highly 
protein bound. Similar conclusions have been reached by Reinarz and 
68 
McIntosh for lincomycin. 
The T-j^0 of intravenously administered clindamycin has been determined 
21 95 44 
in patients with normal ’ and impaired renal function. The present 
study resulted in 3 estimates of T^ (Table 5). When determined by 
analysis of the terminal log-linear portion of the serum decay curve, 
the mean T-^b for the 3 patients studied was 4.55 hours. When plotted 
semilogarithmically, the data for the individual patients revealed that 
loss of antibacterial activity for patient #2 was monoexponential, while 
patients #1 and 5 showed early non-1inearity implying bi-exponential decay. 
Tl/2kel ca^cu^ated Tor the latter two patients was 2.81 hours. Finally, 
the half-life determined from the log-linear portion of the average 
serum decay curve (Fig. 5) was 6.79 hours. 
While the T^ of clindamycin in normals receiving 600 mg intravenously 
21 
was 4.19 hours (range: 2.49 - 5.64) in the study reported by DeHaan, 
44 
Joshi and Stein found the half-life in anephrics not on dialysis to be 
approximately 6 hours. This data indicates prolongation of serum half-life 
in patients with severe renal impairment. The present study shows T-j^b 
and T-j^kgi approximating that seen in normals. 
Looking more closely at the above values (summarized in Table 9), 
the methods of T-^ calculation deserve attention. Although the data 
44 
collected by Joshi and Stein did not yield a straight line when plotted 
semi-logarithmically, graphical analysis of the terminal log-linear portion of 
the average decay curve of 7 patients was used exclusively in the determination 
of the T-j/2 reported. Data from the present study is comparable (6.79 hours) 
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when similarly analyzed. These calculations most likely over-estimate 
the actual T-^. Cimino, et al reported the half-life of orally 
administered clindamycin to be 3.36 hours in patients with end stage 
renal disease. The half-life of orally administered drug in normals 
95 
ranges from 1.50 to 3.54 hours. It is concluded that the half-life 
of clindamycin may not be prolonged in the presence of compromised 
renal function. 
The present study does not permit a firm statement as to drug 
disposition in uremia because of small sample size. However, prolonged 
T-jin uremics receiving clindamycin might be expected since Reinarz 
c 68 
and Min tosh have shown a similar effect on the disposition of lincomycin, 
the chemically similar parent compound. The half-life in anephrics was 
found to be approximately 13 hours, while in normals T-j^ = 4.76. 
Additionally, peritoneal dialysis was shown to have no effect on serum 
T-j/2* Of note is the use of 2-compartment analysis similar to that used 
in the present study. Both the larger sample size and the use of the 
above model for kinetic analysis make this report reliable. It is to 
be expected, therefore, that serum T-^ of clindamycin in anephrics should 
be similarly prolonged. Further investigation, with larger sample size, 
and adequate data analysis is needed. It is concluded from the present 
study, however, that peritoneal dialysis has no effect on clindamycin 
disposition. 
The area under the serum decay curve of clindamycin (Fig. 5) determined 
by the trapazoidal rule was 49.88 (mcg/ml)(hour). Similar calculations 
for normals receiving an identical initial intravenous dose yielded a 
21 
value of 35.1. Comparison reveals the total administered dose of 
36 

clindamycin to be significantly greater in anephrics than in normals. 
It was stated earlier that clindamycin is an antibiotic with 
activity against gram-positive and gram-negative aerobic and anaerobic 
pathogens. Based on the results of the present investigation, the 
following recommendation as to the use of this agent in the patient 
population studied can be made: 
In view of the higher peak and mean antibiotic levels achieved in 
anephric patients, adequate serum concentrations can be attained at a 
lower administered dose. The present study showed peak serum levels 
to be approximately 2-fold greater than those achieved in normals. In 
44 
agreement with Joshi and Stein, it is suggested that the amount of 
clindamycin administered intravenously to anephrics should be approximately 
one-half that required to achieve the desired serum level in patients with 





1. Peak serum levels of tobramycin in functionally anephric patients 
were less than expected, probably secondary to larger volume of distribution. 
2. Peritoneal dialysis leads to significant clearance of this 
antibiotic with a resultant reduction in serum half-life. 
3. Tobramycin disposition in functionally anephric patients without 
peritoneal inflammation and undergoing peritoneal dialysis, appears to 
be similar to the pharmacokinetics of kanamycin. 
4. If bactericidal serum levels of tobramycin are to be maintained, 
it is recommended that a parenteral loading dose be administered, followed 
by either (i) an identical dose every third half-life, or (ii) one-half 
the loading dose every half-life. In the presence of peritonitis, it is 
recommended that a parenteral loading dose be given, followed by intra- 
peri toneal antibiotic administration every 12 hours. 
B. Clindamycin 
1. Peak serum levels of clindamycin in functionally anephric patients 
were approximately 2-fold greater than those expected in normals after an 
identical parenteral dose. It is, therefore, recommended that the administered 
dose of this agent be one-half of that required to produce desired peak 
serum levels in patients without renal impairment. 
2. Peritoneal clearance of clindamycin during dialysis was shown to be 
essentially zero. It is concluded that dialysis does not affect clindamycin 
disposition in this patient population. 
3. Small sample size in the present study did not permit accurate 
estimation of serum half-life. 
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Clearance (C) of Tobramycin, Amount of Drug Removed After 
12 Hours of Dialysis, and Average Peritoneal Dialysate Concentration 
Patient C Amount Removed Dialysate 
(ml/min) (mg) (mcg/ml) 
1 
? 
20.01 22.48 0.98 
3 12.31 17.30 0.79 
4 12.73 18,79 0.81 
5 14,86 25.43 1 .07 
Mean SE 14.98 ± 1.77 21.00 ± 1.83 0.91 ± 0.07 
Table 3 
Tl/2 Tobramycin (hours) 
Patient Tl/2b T1/2kel 
1 19.25 10,52 
2 16.50 8.90 
3 19,25 13.05 
4 8.88 
5 16.50 10.50 
Mean SE 16.08 ±1.90 10.74 ± 0.84 
Ti/2 calculated from the terminal log-linear 
portion of the average serum decay curve 
(Fig. /1) = 14.44 hours. 
•'Ml!. . •.■'/llli'MU 
1 
Table 4 
Volume of Distribution of Tobramycin 
Patient 
vd 
%BW <vd)b %BW 
1 31.28 44.10 32.77 46.15 
2 16.07 29.49 15.71 28.83 
3 23.29 40.43 23.89 41 .48 
4 16.48* 27.93 
5 19.88 29.76 19.33 28.94 
Mean SE 21 .40± 2. 79 34. 34 ± 3. 30 22.93 ± 3.68 36 i.35 ±4.41 




of Clindamycin (hours) and Concentration of 
Antibiotic in Peritoneal Dialysate (mcg/ml) 
Patient T 1 / 2b Tl/2kel alysate 
1 5.02 3.73 1.42 
2 2.22* — 2.53 
5 6.42 1 .89 1.49 
Mean SE 4.55 ± 1.23 2 81 ± 0.92 1.81 ± 0.36 
T-|/2 calculated from the terminal log-linear portion of the average serum 
decay curve (Fig. 5) = 6.79 hrs. 
*Patient #2 displayed monoexponential serum decay of drug activity. 
**Assay for clindamycin was performed on dialysate from exchanges 1, 
3, and 6, Only exchange 1 had any detectable antibiotic activity. 
rim. 
Table 6 
Coefficients and hybrid rate constants for the equation 
n -at . n -bt 
y = Ae + Be 
Antibiotic: Tobramycin 
Pt # A B a b 
kel 
1 1.28 2.11 0.0164 0.0007 0.0011 
2 4.32 3.24 0.0101 0.0006 0.0013 
3 1.19 2.38 0.0176 0.0006 0.0009 
4* — 3.35 0.0013 
5 1.84 3.36 0.0134 0.0007 0.0011 
Antibiotic: Clindamycin 
Pt # 
1 4.89 11.70 0.0146 0.0023 0.0017 
2* — 12.22 — 0.0052 
5 14.37 2.98 0.0124 0.0018 0.0061 
*Patients #4 and #2 displayed monoexponential serum decay of drug activity. 
'ivt j.lms; .'no:'> vio > i n.!ii l>nr< ,’ 1 iv' i .> i T ] -nO 
n r r viMG'rr!oT : o L+o rr 5 11A. 
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Comparative Mean Clearance Values 
of Urea and Creatinine 
(ml/min) 
Patients # pts C urea C cr C /C cr' urea 
tCRF 
(publ ished) 




4 26.82 ± 1.28 23.99 ± 0.17 0.91 ± 0.04 
*Mean ± SE 
tChronic renal failure 
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BUN and Creatinine During 12 Hours 








1 ^control 62 12.8 
1.5 62 12.9 
6.5 51 11.0 
12.5 46 10.9 
2 control 129 15.3 
1.5 127 13.7 
6.5 117 13.2 
12.5 106 13.1 
3 control 65 9.2 
1.5 65 8.8 
6.5 55 8.0 
12.5 49 7.4 
4 control 67 16.5 
1.5 69 16.5 
6.5 58 14.4 
12.5 48 13.1 
5 control 75 21.2 
1 .5 74 20.2 
6.5 65 16.8 
12.5 56 16.8 





Patient #1 J.R. 
T ime Plate I 






730 1 .29 
Plate II Mean SD 
3.31 3.29 0.04 
2.44 2.41 0.04 
2.19 2.11 0.11 
1 .74 1.65 0.13 
1.71 1.58 0.18 
1.32 1.31 0.02 
Dialysate Assay 
(mg/ml) 
Exchange Plate I Plate II Mean 
1 1.61 1 .31 1 .46 
2 1.21 1 .17 1 .10 
3 1.15 1.05 1 .10 
4 1.10 1.03 1 .07 
5 0.98 0.94 0.96 
6 0.83 0.86 0.85 
7 0.82 0.77 0.80 









0.21 2130 3.11 21.51 
0.03 2100 2.50 19.75 
0.07 2050 2.48 21.31 
0.05 2440 2.51 23.39 
0.03 1940 1 .86 17.51 
0.02 2120 1.80 18.20 
0.04 2210 1.77 18.65 
0.04 2120 0.97 11.87 





Patient #2 T.M. 
T ime Plate I 







Plate II Mean SD 
7.32 7.36 0.05 
5.45 5.19 0.37 
4.03 4.21 0.26 
2.88 2.67 0.30 
2.78 2.57 0.31 
2.02 2.10 0.11 
Dialysate assay was not performed for patient #2 




Patient #3 R.W. 
T ime Plate I 





430 1 .91 
730 1.67 
Plate II Mean SD 
3.61 3.47 0.20 
2.56 2.68 0.16 
2.37 2.29 0.11 
1.89 1 .96 0.10 
1 .91 1 .91 0.00 
1.46 1.57 0.11 
Dialysate Assay 
(mcg/ml) 








1 1.15 1 .24 1 .20 0.06 2475 2.97 18.47 
2 0.87 0.99 0.93 0.08 2350 2.19 15.91 
3 0.76 0.83 0.80 0.05 2060 1 .65 12.50 
4 0.77 0.87 0.82 0.07 860 0.71 5.58 
5 0.77 0.79 0.72 0.10 1640 1 .18 9.64 
6 0.65 0.68 0.68 0.01 2050 1 .39 11.85 
7 0.67 0.64 0.65 0.01 2150 1 .40 12.19 
12 0.55 0.54 0.55 0.01 1840 1 .01 10.74 
Mean 0.79 1 .56 
v\ 
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Patient #4 J.J. 
Time Plate I 













Plate II Mean SD 
3.22 3.08 0.21 
2.84 2.76 0.11 
2.11 2.09 0.03 
1.94 1.96 0.03 
1 .14 1 .26 0.17 
1 .01 0.99 0.03 
Dialysate Assay 
(mcg/ml) 








1 1.29 1.34 1.32 0.04 2290 3.02 16.36 
2 1.01 1.15 1.08 0.10 2345 2.53 15.29 
3 0.86 0.88 0.87 0.01 1950 1.70 10.81 
4 0.71 0.84 0.78 0.09 2170 1 .69 11.64 
5 0.82 0.83 0.83 0.01 2715 2.25 16.74 
6 0.71 0.77 0.74 0.04 2080 1.54 12.27 
7 0.61 0.66 0.64 0.04 1090 0.70 6.03 
12 0.22 0.24 0.23 0.01 5903 1 .36 17.96 
Mean 0.81 1 .85 
n ■ :\ -’r. y 1K'" >: .V 
\' ' > v:-* 
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Patient #5 J.T. 
Time Plate I Plate II Mean SD 
(min post infusion) 
5 4.12 4.91 4.52 0.56 
70 3.22 2.94 3.08 0.20 
130 3.17 2.97 3.07 0.14 
370 2.84 2.41 2.62 0.29 
430 2.60 2.17 2.39 0.30 
730 2.00 1 .96 1 .98 0.03 
Dialysate Assay 
(mcg/ml) 








1 1.47 1.72 1.60 0.18 2400 3.84 20.78 
2 1 .16 1.30 1.23 0.10 2360 2.80 15.76 
3 0.93 0.97 0.95 0.03 2000 1 .00 10.81 
4 0.51 0.46 0.49 0.04 2050 2.49 5.98 
5 1.38 1 .39 1 .39 0.01 2150 2.99 18.59 
6 1.10 1 .09 1 .10 0.01 2200 2.42 15.39 
7 1.09 1 .08 1 .09 0.01 1820 1.98 16.70 
12 0.73 0.70 0.72 0.02 2050 1 .48 22.57 
Mean 1 .07 2.31 
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(min post infusion) 
Plate I Plate II Mean SD 
Patient #1 J.R. 
5 15.61 15.66 15.64 0.04 
30 — 
70 12.20 12.00 12.10 0.14 
160 8.67 8.40 8.54 0.19 
340 4.70 5.32 5.01 0.44 
520 3.85 3.72 3,79 0.09 
700 2.50 2.65 2.58 0.11 
Patient #2 T.M. 
5 13.62 13.96 13.78 0.25 
30 11.28 11 .50 11.39 0.16 
70 9.34 9.16 9.25 0.13 
160 5.65 5.59 5.62 0.04 
340 1.48 1 .57 1 .53 0.06 
520 0.68 0.69 0.69 0.01 
700 0.64 0.67 0.66 0.02 
Patient #5 J.T. 
5 17.00 16.63 16.82 0.26 
30 12.28 11.78 12.03 0.35 
70 9.17 8.73 8.95 0.31 
160 4.31 4.64 4.48 0.23 
340 1 .52 1 .50 1.51 0.01 
520 1 .05 1 .11 1.08 0.04 
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Patient Consent Form for Participation in A Clinical Investigation Project 
Yale University School of Medicine 
Yale—New Haven Hospital 
Description of Project: 
We would like to ask you to participate in a study involving the use of a new 
antibiotic Clindamycin/Tobramycin in people who need peritoneal dialysis. The 
purpose of the investigation is to measure the amount of antibiotic in your 
bloodstream while you are receiving peritoneal dialysis in the hospital. 
Ordinarily antibiotics are used to treat infections. Since you have no infection 
administration of this antibiotic will be of no value to you. The purpose of 
this study is to obtain information which could be of importance to others 
requiring dialysis who do have infections. You are free to refuse to participate 
in this study or to withdraw from the study at any time. Your refusal or withdrawal 
will not affect your future care at this institution. 
Authorization: I have read the above and agree to the participation of 
(name or names and how related) 
in the project described above. Its general purposes, potential benefits, and possible hazards and inconveniences have been 
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